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Abstract 1 
Purpose: A high phase angle measured by the Nutriguard® bioelectrical impedance analysis 2 
device is associated with a reduced mortality risk in older people. This retrospective study 3 
aims to analyze whether this association persists with the other devices that have been used in 4 
our hospital.  5 
Methods: This study encompasses all people 65 yrs and older who underwent a phase angle 6 
measurement between 1990 and 2011 at the Geneva University Hospitals, with the RJL-101® 7 
(RJL Systems), Xitron 4000B® (Xitron Technologies), Eugedia® (Eugédia-Spengler) and Bio-8 
Z® (Spengler). Diseases at the time of phase angle measurement were reported in the form of 9 
the Cumulative Illness Rating Scale. Date of death was retrieved until December 2012. Phase 10 
angle values were categorized into sex- and device-specific quartiles, where quartile 1 11 
represents the lowest quartile and reference value. Cox regressions were performed to 12 
evaluate the association between phase angle quartiles and mortality.  13 
Results: We considered 1878 people (969 women), of whom 1151 had died. In univariate 14 
sex-specific Cox regressions, the death risk decreased progressively as the phase angle 15 
quartile measured by the Bio-Z® or RJL-101® increased. The HR (95% CI) in quartile 4 was 16 
0.36 (0.26, 0.50) and 0.38 (0.29, 052) in women and men measured with the Bio-Z® (both 17 
p<0.001), and 0.23 (0.14, 0.39) and 0.19 (0.10, 0.36) in women and men measured with the 18 
RJL-101® (both p<0.001). The association between phase angle and mortality persisted when 19 
adjusted for age, body mass index or co-morbidities. The small number of deaths in people 20 
who underwent a measurement by Eugedia® (n=93) or Xitron4000B® (n=56) did not allow 21 
performing multivariate Cox regressions.  22 
Conclusions: Phase angle quartiles are associated with mortality in people aged >65 years 23 
when using the RJL-101® or Bio-Z device®.  24 
 25 
Keywords: bioimpedance, older people, death  26 
Introduction 27 
An increasing interest arises in the potential of phase angle to predict adverse outcomes 28 
like mortality (1-3). Phase angle is a raw bioelectrical impedance analysis (BIA)-derived 29 
parameter which may reflect cell size, cell membrane integrity and/or the distribution of water 30 
in the extra- and intracellular compartments (4) (5). Mathematically, it can be obtained from 31 
the arctangent of the reactance to resistance ratio measured by BIA. Thus, phase angle values 32 
do not depend on equations and their inherent assumptions, in contrast to BIA-derived body 33 
composition, i.e. fat mass and fat-free mass.  34 
In a recently published cohort study, we have included all people ≥ 65 yrs who had 35 
undergone a BIA measurement at the Geneva University Hospitals between 1990 and 2011 36 
(n=3181) (6). Mortality was reported until December 2012. We have shown that the lower the 37 
phase angle quartile at the last BIA measurement performed with the Nutriguard® device 38 
(n=1307) (Data Input GmbH, Darmstadt, Germany), the higher was the death risk, 39 
independently of the co-morbidities (7). We had focused on the measurements performed 40 
with the Nutriguard® device because 1) this device is still used in our hospital, and 2) phase 41 
angle reference values using the same brand of BIA device have been published (8) and 42 
allowed us to standardize the values for age and body mass index (BMI).  43 
However, we have not reported the association of mortality and the phase angle measured 44 
by the other BIA devices that we have used over the time span of 21 years. The rationale of 45 
performing additionally these analyses is that, in the absence of a gold standard, phase angle 46 
values likely differ between devices. This retrospective study aims to analyze whether phase 47 
angle values measured by the other BIA devices than the Nutriguard® are also associated with 48 
mortality.  49 
 50 
Material and methods 51 
We included the remaining 1878 people of our previously described cohort study (6), 52 
which encompassed all people ≥65 yrs who underwent a BIA measurement at the  Geneva 53 
University Hospitals between 1990 and 2011.  This study population included hospitalized 54 
and ambulatory patients followed in clinical routine by the nutrition unit, and healthy people 55 
recruited for research purpose in leisure clubs, the hospital staff, at fun runs and through 56 
advertisement in local newspapers. The proportion of hospitalized patients was about 50% 57 
(n=967). BIA measurements were performed at 50kHz and 0.8 mA, while the subject was 58 
lying in the supine position with electrodes placed on the right hand, wrist, angle and foot. 59 
The following devices were used: RJL-101® (1990 to 1995) (RJL Systems, Inc., Clinton 60 
Township MI, USA), Xitron 4000B® (1990 to 2011) (Xitron Technologies, San Diego, CA, 61 
USA), Eugedia® (1994 to 2000) (Eugédia-Spengler, Cachan, France) and Bio-Z® (1996 to 62 
2002) (Spengler, Paris, France).  All devices were calibrated for phase angle with a 63 
calibration jig (CJ 4000, Xitron Technologies, San Diego, CA, USA), before their use in our 64 
institution. A limit of ±2° for phase angle and ±5Ω for impedance was tolerated at 50 kHz. To 65 
test method agreement, we had measured the phase angle values of 8 healthy people with the 66 
RJL-101®, the Xitron®, and the Bio-Z®, without changing the position of the people nor the 67 
placement of the electrodes. Method agreement, calculated as the mean phase angle difference 68 
(2SD) obtained from the Bio-Z® minus the RJL-101® or the Xitron®, was -1.49° (0.45) and -69 
1.50 (0.24), respectively. We also calculated fat-free mass with the Geneva formula (9), 70 
which was validated against DXA specifically in older persons (10). Fat mass was obtained 71 
by subtracting fat-free mass from body weight. Fat-free mass index and fat mass index were 72 
calculated as follows: fat-free mass or fat mass (kg)/body height (m)2. 73 
Date of death was considered until December 2012, and retrieved from the hospital 74 
computer database, the death registry of the state of Geneva and the Swiss National Cohort 75 
(11). We reported co-morbidities at the time of the BIA measurement in the form of the 76 
Cumulative Illness Rating Scale (CIRS) (12). It rates 14 systems and organs from 0 (healthy) 77 
to 4 (severe disease needing immediate intervention or hospitalization), and takes into account 78 
lifestyle modes as smoking and alcohol consumption. Its final score ranges from 0 (healthy) 79 
to 56 points. 80 
 81 
Statistics 82 
Results are shown as median (interquartile range) for continuous variables as they were not 83 
normally distributed according to Shapiro-Wilk tests. Comparisons between devices were 84 
performed with Kruskall-Wallis test.  85 
Age, body mass index and CIRS were categorized like in our former study, because their 86 
distribution, tested by Shapiro-Wilks test, was not normal: age as 65-74 yrs, 75-84 yrs and 87 
≥85 yrs, BMI as <18.5, 18.5-24.9, 25-29.9 and ≥30 kg/m2 (13), and CIRS as quartiles of the 88 
population measured by the considered device. The association between mortality and device- 89 
and gender-specific phase angle quartiles were evaluated by univariate Cox regressions. We 90 
performed multivariate Cox regressions with adjustments for age (model 1), BMI (model 2) 91 
or CIRS categories (model 3) because we did not observe enough events to follow the rule of 92 
Harrel (14). This rule supposes a maximum of 1 variable for 10 events. 93 
 94 
Results 95 
The characteristics of the study subjects measured by the different BIA devices are shown 96 
in table 1. They were significantly different regarding age, body mass index, co-morbidities 97 
and phase angle. 98 
The small number of deaths in women (n=16) and men (n=39) who underwent a BIA 99 
measurement by Xitron 4000B precluded the use of sex-specific phase angle quartiles in the 100 
Cox regressions. We thus focused on the three other devices (n=1683). In sex-specific 101 
univariate Cox regressions, the association between phase angle quartiles measured with the 102 
Bio-Z® and RJL-101® devices and mortality could be highlighted, although the cut-off 103 
quartiles differed between the BIA devices (table 2).  No associatation between phase angle 104 
and mortality was observed when using the Eugedia® device. Sex-specific multivariate Cox 105 
regressions could be performed with the Bio-Z® and the RJL-101® device (table 3). They 106 
confirmed the findings of univariate Cox regressions even when adjusting for age, BMI or 107 
CIRS categories, i.e. the higher the phase angle quartile, the lower the death risk. 108 
 109 
Discussion 110 
This study shows that the mean phase angle values differed significantly between the 111 
subjects measured with the Bio-Z®, RJL-101®, Eugedia® and Xitron® devices. A low phase 112 
angle quartile was associated with a high death risk in people aged > 65 years, when using a 113 
Bio-Z® or a RJL-101® device. When adjusting for age, body mass index or disease, a low 114 
phase angle remained a risk factor of mortality.  115 
The characteristics of the study population (age, BMI, diseases), or the technology itself 116 
may explain the differences in phase angle values between the devices. Reference values for 117 
phase angle are 7.7 and 10.5 % lower in the Swiss women and men (using several BIA brands 118 
cross-calibrated for resistance) (15), and 12.5 and 16% lower in the German women and men 119 
(using Data Input devices) (8) compared to the American population (using an RJL device) 120 
(16). Bosy-Westphal et al. reported that a discrepancy of 0.3° for phase angle may be related 121 
to differences between the Xitron® and Data Input devices, and that, although age and BMI 122 
influence phase angle values, they do not explain the differences between populations (8). 123 
This suggests that differences of phase angle values between our study groups may be related 124 
to different anthropometric characteristics, BIA devices or other unidentified factors. Thus, 125 
when evaluating the potential of a phase angle value on outcome at a population level, and in 126 
the absence of a gold standard for phase angle measurement, it is essential to use a single 127 
brand of BIA to avoid at least the confounding impact of different BIA devices. 128 
Whether using an RJL-101® or a Bio-Z® device, a phase angle in the low quartile is 129 
associated with a high risk of mortality. This result confirms our previous findings using a 130 
Nutriguard® device but also other studies performed in older persons. A phase angle < 3.5°, 131 
measured by a Nutriguard® device at admission to a German hospital, increased the in-132 
hospital mortality by four times (17). Similarly, a phase angle in the lowest quintile (women: 133 
2.7-5.4°, men: 3.1-5.6°), measured by a Valhalla® device (Valhalla Scientific, San Diego, CA, 134 
USA), led to a two-fold increase of mortality risk at 12 years (18). The adjustment for BMI, 135 
age or CIRS did not change this association in our study. As a consequence, phase angle is 136 
associated with mortality independently of these other mortality risk factors.  137 
This study could demonstrate the link of phase angle and mortality with the RJL-101® and 138 
the Bio-Z devices®, but has several limitations. It is not a population-based study and our 139 
subjects are likely more ill than the general population. However, the link between phase 140 
angle and mortality was confirmed when adjusting for co-morbidities and their severity. We 141 
did not use the different BIA devices in the same study population. This precludes the 142 
comparison of phase angle values. Finally, the number of events (i.e. deaths) was not high 143 
enough to make simultaneous adjustments for age, BMI and co-morbidities in the statistical 144 
analyses.  145 
Future studies should evaluate differences in electrical parameters between commonly 146 
used BIA devices in large populations, in order to differentiate the variations related to 147 
devices vs. population characteristics. They should also better identify the factors which 148 
influence phase angle, especially in interventional studies with a longitudinal follow-up.  149 
 150 
Conclusion 151 
Phase angle quartiles are associated with mortality in people aged ≥ 65 years and older 152 
when using other BIA devices than the Nutriguard®, as the RJL-101® or the Bio-Z®, although 153 
the cut-offs of the phase angle quartiles differ.  154 
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Table 1: Baseline characteristics at the last BIA measurements (n=1683) 227 
 Bio-Z® RJL-101® Eugédia® p* 
 N % median IQR N % median IQR N % median IQR  
Women              
Age (yrs) 424 100 77.0 11.0 266 100 80.0.2 12.0 185 100 75.0 10.0 <0.001 
Age at death (yrs) 301 71 83.4 12.8 150 56 87.0 9.0 89 48 87.6 10.4 <0.001 
Length of follow-up (yrs)# 424 100 5.8 9.2 266 100 15.3 15.1 185 100 16.7 6.6 <0.001 
Phase angle (degrees) 424 100 3.4 1.4 266 100 4.2 1.4 185 100 4.1  1.0 <0.001 
Resistance (Ω) 424 100 577.2 146.6 266 100 602.0 143.0 185 100 558.9 88.0 <0.001 
Reactance (Ω) 424 100 34.8 17.0 266 100 45.0 19.0 185 100 40.0 11.0 <0.001 
Body mass index (kg/m2) 424 100 24.2 7.5 266 100 23.7 5.6 185 100 26.6 6.4 <0.001 
Fat mass index (kg/m2) 424 100 9.3 5.1 266 100 8.6 3.6 185 100 10.5 4.0 <0.001 
Fat-free mass index (kg/m2) 424 100 14.8 3.5 266 100 14.8 2.4 185 100 16.0 3.0 <0.001 
Cumulative Illness Rating Scale 393 93 10.0 8.0 154 58 5.0 5.0 114 62 3.0 5.0 <0.001 
Men              
Age (yrs) 501 100 75.0 10.0 190 100 74.0 12.0 117 100 73.0 10.0 <0.001 
Age at death (yrs) 397 79 78.9 10.8 106 56 82.5 12.7 53 45 83.5 11.2 <0.001 
Length of follow-up (yrs) 501 100 3.4 8.8 190 100 14.7 17.4 117 100 17.1 9.4 <0.001 
Phase angle (degrees) 501 100 3.7 1.7 190 100 4.9 1.8 117 100 4.6  1.7 <0.001 
Resistance (Ω) 501 100 486.5 116.6 190 100 506.5 92.0 117 100 489.1 89.0 <0.001 
Reactance (Ω) 501 100 30.8 13.7 190 100 42.0 17.0 117 100 39.2 10.6 <0.001 
Body mass index (kg/m2) 501 100 24.5 5.6 190 100 24.5 4.2 117 100 26.2 4.8 <0.001 
Fat mass index (kg/m2) 501 100 6.7 3.6 190 100 6.7 3.2 117 100 7.6 3.0 <0.001 
Fat-free mass index (kg/m2) 501 100 18.0 3.6 190 100 18.0 2.3 117 100 18.4 2.8 <0.001 
Cumulative Illness Rating Scale 393 93 10.0 8.0 154 58 5.0 5.0 114 62 3.0 5.0 <0.001 
IQR: interquartile range; # Time between the BIA measurements and death or censoring (31.12. 2011); * Comparisons between devices: Wilcoxon rank-sum U test 228 
229 
Table 2: Univariate Cox regression models evaluating the association of phase angles quartiles, measured by different BIA devices, and mortality. 230 
   Women    Men   
 n Cut-off HR 95% CI n Cut-off HR 95% CI 
Bio-Z® 424    501    
Quartile 1 106 0.10-2.69 1.00 - 126 0.10-2.79 1.00 - 
Quartile 2 106 2.70-3.39 0.63 0.47, 0.85 125 2.80-3.69 0.67 0.52, 0.88 
Quartile 3 106 3.40-4.10 0.41 0.30, 0.57 125 3.70-4.50 0.54 0.42, 0.71 
Quartile 4 106 4.10-7.40 0.36 0.26, 0.50 125 4.50-7.40 0.38 0.29, 0.51 
RJL-101® 266    190    
Quartile 1 67 1.58-3.51 1.00 - 48 0.91-3.85 1.00 - 
Quartile 2 66 3.52-4.18 0.78 0.52, 1.17 47 3.88-4.90 0.76 0.48, 1.20 
Quartile 3 67 4.19-4.93 0.40 0.26, 0.62 48 4.91-5.60 0.36 0.21, 0.61 
Quartile 4 66 4.94-11.64 0.23 0.14, 0.39 47 5.61-9.51 0.19 0.10, 0.36 
Eugédia®  185    117    
Quartile 1 47 0.1-3.5 1.00 - 31 0.9-3.6 1.00  
Quartile 2 46 3.6-4.1 1.39 0.79, 2.42 28 3.7-4.5 0.91 0.42, 1.96 
Quartile 3 46 4.1-4.6 0.69 0.37, 1.28 29 4.6-5.3 1.03 0.50, 2.14 
Quartile 4 46 4.7-6.4 0.72 0.39, 1.32 29 5.4-7.7 0.76 0.35, 1.65 
 231 
  232 
Table 3: Multivariate Cox regression models evaluating the association of phase angles quartiles, measured by different BIA devices, and 233 
mortality. 234 
 Bio-Z® RJL-101® 
 Women Men Women Men 
 n HR 95% CI n HR 95% CI n HR 95% CI n HR 95% CI 
Model  1 424   501   266   190   
Quartile 1  1.00 -  1.00 -  1.00 -  1.00 - 
Quartile 2  0.63 0.47, 0.85  0.67 0.52, 0.88  0.73 0.49, 1.11  0.68 0.42, 1.09 
Quartile 3  0.41 0.30, 0.56  0.56 0.43, 0.73  0.36 0.23, 0.57  0.34 0.20, 0.59 
Quartile 4  0.41 0.29, 0.57  0.41 0.30, 0.54  0.19 0.10, 0.34  0.16 0.08, 0.31 
Model  2 424   501   266   190   
Quartile 1  1.00 -  1.00 -  1.00 -  1.00 - 
Quartile 2  0.62 0.46, 0.85  0.70 0.53, 0.91  0.78 0.52, 1.18  0.75 0.47, 1.20 
Quartile 3  0.40 0.29, 0.56  0.58 0.44, 0.76  0.41 0.26, 0.63  0.35 0.20, 0.62 
Quartile 4  0.35 0.25, 0.49  0.42 0.31, 0.57  0.23 0.14, 0.39  0.19 0.10, 0.35 
Model  3 393   481   154   107   
Quartile 1  1.00 -  1.00 -  1.00 -  1.00 - 
Quartile 2  0.77 0.57, 1.04  0.71 0.54, 0.93  0.73 0.45, 1.19  0.67 0.40, 1.12 
Quartile 3  0.55 0.39, 0.76  0.66 0.50, 0.87  0.42 0.25, 0.71  0.48 0.25, 0.91 
Quartile 4  0.53 0.38, 0.75  0.51 0.38, 0.68  0.42 0.22, 0.77  0.36 0.16, 0.78 
Model 1: adjusted for age category; model 2: adjusted for BMI category; model 3: adjusted for CIRS quartiles 235 
 236 
